Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M
Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel.
Neurology. 2007 Oct 2;69(14):1404-10. doi: 10.1212/01.wnl.0000277487.04281.db.
Ischemic animal model studies have shown a neuroprotective effect of minocycline.
To analyze the effect of minocycline treatment in human acute ischemic stroke.
We performed an open-label, evaluator-blinded study. Minocycline at a dosage of 200 mg was administered orally for 5 days. The therapeutic window of time was 6 to 24 hours after onset of stroke. Data from NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI) were evaluated. The primary objective was to compare changes from baseline to day 90 in NIHSS in the minocycline group vs placebo.
One hundred fifty-two patients were included in the study. Seventy-four patients received minocycline treatment, and 77 received placebo. NIHSS and mRS were significantly lower and BI scores were significantly higher in minocycline-treated patients. This pattern was already apparent on day 7 and day 30 of follow-up. Deaths, myocardial infarctions, recurrent strokes, and hemorrhagic transformations during follow-up did not differ by treatment group.
Patients with acute stroke had significantly better outcome with minocycline treatment compared with placebo. The findings suggest a potential benefit of minocycline in acute ischemic stroke.
缺血性动物模型研究已显示米诺环素具有神经保护作用。
分析米诺环素治疗对人类急性缺血性卒中的影响。
我们进行了一项开放标签、评估者盲法研究。口服剂量为200 mg的米诺环素，持续5天。治疗时间窗为卒中发作后6至24小时。评估美国国立卫生研究院卒中量表（NIHSS）、改良Rankin量表（mRS）和Barthel指数（BI）的数据。主要目的是比较米诺环素组与安慰剂组从基线到第90天NIHSS的变化。
152例患者纳入研究。74例患者接受米诺环素治疗，77例接受安慰剂治疗。米诺环素治疗的患者NIHSS和mRS显著更低，BI评分显著更高。这种模式在随访第7天和第30天就已明显。随访期间的死亡、心肌梗死、复发性卒中和出血性转化在治疗组之间无差异。
与安慰剂相比，急性卒中患者接受米诺环素治疗的结局显著更好。这些发现提示米诺环素在急性缺血性卒中可能有益。
Zotero 插件